TP53 and breast carcinoma: reported that metabolomic integrated genomics analysis may hold promise for understanding multidrug resistance phenotypes in MCF-7 breast cancer cells exposed to adriamycin by modulating the ABCA1/EGFR/P53/PI3k/PTEN signalling pathway (40).